Notice of Intent to Sole Source – Therakos, Inc.
ID: 24-013006Type: Special Notice
Overview

Buyer

HEALTH AND HUMAN SERVICES, DEPARTMENT OFNATIONAL INSTITUTES OF HEALTHNATIONAL INSTITUTES OF HEALTH - CCBETHESDA, MD, 20892, USA

NAICS

Surgical and Medical Instrument Manufacturing (339112)

PSC

MEDICAL AND SURGICAL INSTRUMENTS, EQUIPMENT, AND SUPPLIES (6515)

Original Source

https://sam.gov/opp/b0c00c34934546abb3d51c744459f431/view
Timeline
    Description

    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), intends to award a sole source contract to Therakos, Inc. for the urgent procurement of Uvadex (methoxsalen) Sterile Solution for the NIH Clinical Center's Central Pharmacy. This acquisition is critical for providing necessary pharmaceutical supplies, specifically 20 mcg/mL Uvadex in cartons, to meet immediate healthcare needs. The contract will be awarded under the Simplified Acquisition Procedures, allowing for a sole source determination due to the urgency of the requirement. Interested parties may express their interest and capabilities to Kristin Nagashima at kristin.nagashima@nih.gov by September 10, 2024, at 3 PM EST.

    Point(s) of Contact
    Kristin Nagashima
    kristin.nagashima@nih.gov
    Files
    No associated files provided.
    Lifecycle
    Title
    Type
    Notice of Intent to Sole Source – Therakos, Inc.
    Currently viewing
    Special Notice
    Similar Opportunities
    Hardy Diagnostic Reagents and Supplies
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking to award a sole-source contract to Hardy Diagnostics for the procurement of culture media and organism supplies necessary for cGMP Sterility Testing Services. The primary objective is to ensure compliance with FDA regulations by utilizing cGMP quality materials that have been rigorously validated, as these supplies are critical for the isolation and identification of pathogens affecting critically ill patients. The contract will cover a base period of twelve months with an option for an additional three months, and interested vendors capable of providing similar products are encouraged to submit capability statements by the specified deadline. For further inquiries, potential respondents may contact Kimala Winfield at kimala.winfield@nih.gov or Malinda Dehner at dehnerm@cc.nih.gov.
    Notice of Intent to Sole Source – Articulate Global
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), intends to award a sole source contract to Articulate Global, LLC for the renewal of licenses for the Articulate 360 suite of e-learning authoring tools. This procurement aims to provide the NIH Clinical Center Nursing Department with continued access to a suite of customizable tools essential for developing and maintaining over 60 online courses that have been created since 2015. The renewal is critical as it allows the Nursing Department to efficiently update existing courses without the need to transition to a new vendor, which would significantly disrupt their operations. Interested parties may express their interest and capabilities by contacting Kristin Nagashima, Contract Specialist, via email at Kristin.nagashima@nih.gov by January 17, 2025, at 5 PM EST.
    6505--ILLUCCIX PSMA VASD
    Veterans Affairs, Department Of
    The Department of Veterans Affairs (VA), through the Network Contracting Office (NCO) 22, intends to award a sole source firm-fixed price contract to Cardinal Health 414, LLC for the procurement of Illuccix PSMA radioactive therapy injections. This procurement is justified under FAR 8.405-6(a)(1)(B), as only one source can provide the unique supplies necessary for treating prostate cancer patients undergoing Positron Emission Tomography (PET) imaging. The Illuccix PSMA injection is FDA approved for patients with prostate cancer, particularly for those whose cancer may have metastasized or recurred, making it a critical component in their treatment. Interested parties must submit a tailored capability statement and relevant company information by 10:00 AM PT on January 21, 2025, to Hestia.Sim@va.gov, as the VA reserves the right to proceed with Cardinal Health if no adequate responses are received.
    Acquisition of SomaScan 7K and 11K Assay Kits
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking to procure fifty-nine (59) SomaScan 7K and/or 11K Assay Kits on a sole source basis from SomaLogic Operating Co., Inc. This acquisition is intended to support the Center for Human Immunology, Inflammation, and Autoimmunity (CHI) in their systems biology research, which involves measuring a wide range of proteins in various human biological samples to enhance understanding of the immune system and related diseases. The procurement aligns with federal initiatives to advance health science research capabilities, with an estimated delivery date for the products set for December 20, 2024, and a performance period from February 21, 2025, to February 20, 2026. Interested vendors may contact Kathy Song at kathy.song@nih.gov for further information and must submit their capabilities statements within 15 days of this notice.
    J--Maintenance Contract for BD Fortessa Flow Cytometer Analyzer
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking to award a sole source maintenance contract for the BD Fortessa Flow Cytometer Analyzer. The contract will be awarded to Becton, Dickinson and Company, which is uniquely qualified to provide comprehensive maintenance services, including emergency repairs and two annual preventative visits, due to the proprietary nature of the cytometer's configurations tailored for the NIH's research needs. This specialized equipment is critical for ongoing research in hematology, necessitating high uptime to support scientific advancements. Interested parties may express their capabilities, with responses due by January 17, 2025; for further inquiries, contact Helmut A. Winffel at helmut.winffel@nih.gov or +1 301 435 0330.
    Preventative Maintenance 10x Genomics Chromium iX/X
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking to award a sole-source contract to 10x Genomics, Inc. for preventative maintenance of the Chromium X single cell capture system, which is critical for ongoing research in neural regeneration. The contract aims to ensure the operability of the equipment, minimize downtime, and support the generation of sequencing libraries necessary for the Molecular Neurobiology Section's research efforts. This maintenance service is essential for maintaining the functionality of the proprietary equipment, which requires OEM-certified technicians and compatible parts, as no alternative suppliers are available. Interested parties can contact Frederick Weddington at frederick.weddington@nih.gov or by phone at 301-594-6835, with the response date for proposals set for January 17, 2025, and the performance period expected to run from January 27, 2025, to January 26, 2030.
    Chemistry, Manufacturing and Controls and Related Services for Development of Drug Products
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the National Institutes of Health (NIH), is seeking proposals for Chemistry, Manufacturing, and Controls (CMC) services to support the development of drug products. The objective of this procurement is to ensure the delivery of high-quality formulated drug products for preclinical, IND-enabling, and clinical studies, which are critical for advancing therapeutic development. This opportunity encompasses a wide range of services, including formulation development, manufacturing under current Good Manufacturing Practices (cGMP), and necessary testing to meet regulatory standards. Proposals are due by February 3, 2025, with a contract period extending from September 30, 2025, to July 31, 2031, and a maximum funding amount of $49,885,703. Interested parties can contact Michelle Cecilia at michelle.cecilia@nih.gov or Valerie Whipple at valerie.whipple@nih.gov for further information.
    INTENT TO SOLE SOURCE - CAREFUSION for Pyxis rental with full support
    Health And Human Services, Department Of
    Special Notice: HEALTH AND HUMAN SERVICES, DEPARTMENT OF intends to negotiate a sole source contract with CareFusion Solutions for Pyxis rental with full support. Pyxis is a drug automated distribution system that controls the availability, access distribution, and patient safety. The contract will be in effect from the date of award to March 31, 2025. This is a non-competitive procurement based on exclusive licensing agreement. Other potential sources may submit a capability statement by July 24th, 2024.
    NIAID CLINICAL PRODUCTS CENTER (CPC)
    Health And Human Services, Department Of
    The National Institutes of Health (NIH), specifically the National Institute of Allergy and Infectious Diseases (NIAID), is seeking proposals for a contract to provide pharmacy and pharmaceutical oversight for clinical trials, both nationally and internationally. The primary objective of this contract is to ensure the integrity of study products, participant safety, and compliance with pharmacy and pharmaceutical regulations throughout various NIH-funded clinical trials. This opportunity is critical for maintaining high standards in public health research, as it encompasses a wide range of services including product management, regulatory document maintenance, and clinical laboratory testing. Proposals are due by January 17, 2025, with the contract expected to commence on April 1, 2026, and run through March 31, 2027, potentially extending through 2033. Interested parties can contact Deborah Blyveis at blyveisd@niaid.nih.gov or Emily Bannister at emily.bannister@nih.gov for further information.
    Notice of Intent BD Rhapsody Single-Cell Analysis Reagent Kits
    Health And Human Services, Department Of
    Notice of Intent BD Rhapsody Single-Cell Analysis Reagent Kits The Department of Health and Human Services, Department of, National Institutes of Health, is planning to procure BD Rhapsody Single-Cell Analysis Reagent Kits. These kits are used for the manufacture of human cells and tissue-based products utilized in phase I/II clinical protocols for transplantation, adoptive immunotherapy, and gene therapy conducted in the Clinical Center at the NIH. The procurement includes a standing order for multi-type sequencing kits and reagents with a short shelf life. The contractor will be responsible for shipping the sufficient reagents and kits following the scheduled delivery dates. The shelf life of the sequencing reagents should be at least 3 months, and the shelf life of library generation kits should be at least 6 months. The contractor is also required to provide technical support for all kits and reagents at no additional cost. The period of performance for this procurement is from 5/1/2024 to 8/30/2024. The delivery schedule is overnight delivery Monday through Thursday to the Center for Cellular Engineering (CCE) at NIH/CC in Bethesda, MD. The vendor will be responsible for ensuring the safe transport of cryopreserved patient cells and maintaining the temperature and other parameters during the shipment of reagents and kits. The contractor will be paid per product delivered and is required to provide hard copies of proofs of each product delivered. Interested parties can submit their capabilities to the Office of Purchasing and Contracts by May 1st, 9:00 AM EST. Please note that this is not a request for proposal.